Leukaemia Trial, Recruiting NCT06513273 Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT06513273
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with a type of blood cancer called Acute Myeloid Leukaemia (AML), according to specific medical guidelines, but not a subtype known as M3
  • People who have agreed to take part by signing a consent form (where this applies)
  • People who are starting treatment with certain newer AML medicines, either alone or in combination with other drugs, approved by the Italian medicines authority (AIFA) between the start of the study and 31 December 2027 — this includes people with a specific gene change called FLT3 being treated with a medicine called gilteritinib, people with a gene change called IDH being treated with IDH-blocking medicines, people receiving a maintenance treatment called oral azacitidine, or people being treated with medicines called glasdegib or gemtuzumab ozogamicin, as well as other newly approved AML medicines that may become available during the study period

Who may not be able to join:

  • People who are already taking part in another clinical trial that involves a specific treatment being tested (known as an interventional clinical trial)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Anna Candoni, Haematology, University of Modena and Reggio Emilia

Phone: 0670390528

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Registry
ClinicalTrials.gov
Start date
11 July 2025
Est. completion
1 December 2029

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

New therapies efficacy in terms of Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov